Blancas, IsabelMartin-Perez, Francisco JGarrido, Jose MRodriguez-Serrano, Fernando2023-02-092023-02-092020-09-01Blancas I, Martín-Pérez FJ, Garrido JM, Rodríguez-Serrano F. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients. Breast. 2020 Dec;54:106-113.http://hdl.handle.net/10668/16317Trastuzumab is a drug used in HER2-positive breast cancer that increases patient survival. Due to cardiotoxicity is the most important side effect of trastuzumab treatment, cardiac monitoring should be a priority. The purpose of this study is to evaluate plasma NT-proBNP level and major cardiovascular risk factors as possible early predictors of trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients. We conducted a retrospective observational study involving 66 patients with HER2-positive breast cancer treated with trastuzumab. Left ventricle ejection fraction (LVEF), NT-proBNP values, and the history of cardiovascular risk factors were collected. Cardiotoxicity was diagnosed considering a decrease of the LVEF from baseline or clinical manifestation of congestive heart failure. NT-proBNP cut-off points were considered to establish normal or abnormal values according to patient age. 27.3% of the patients suffered cardiotoxicity during trastuzumab treatment. Most cases were diagnosed due to the appearance of cardiac symptomatology (66.7%). Logistic regression analysis showed a significant association of diabetes mellitus (OR 5.9, 95% CI 1.2-28.5, p = 0.028) and high NT-proBNP levels (OR 22.0, 95% CI 5.7-85.4, p  NT-proBNP levels above the upper limit of the normal range adjusted to age or diabetes mellitus seem to be associated with a higher risk of developing cardiotoxicity. However, some limitations of the present study make necessary further studies aimed to clarify whether NT-proBNP and diabetes-associated markers determinations can be useful in the monitoring of cardiotoxicity risk in breast cancer patients undergoing trastuzumab therapy.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Breast cancerCardiotoxicityEarly diagnosisHER2NT-proBNPTrastuzumabAdultAgedAntineoplastic AgentsBiomarkers, PharmacologicalBreast NeoplasmsCardiotoxicityDiabetes MellitusDrug MonitoringFemaleHeart Disease Risk FactorsHeart FailureHumansLogistic ModelsMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPredictive Value of TestsReceptor, ErbB-2Retrospective StudiesStroke VolumeTrastuzumabVentricular Function, Leftresearch article32977298open accessAntineoplásicosBiomarcadores farmacológicosDiabetes MellitusCardiotoxicidadEstudios retrospectivosFactores de riesgo de enfermedad cardiacaFragmentos de péptidosFunción ventricular izquierdaInsuficiencia cardíacaMonitoreo de drogasModelos logísticosNeoplasias de la mamaPéptido natriurético encefálicoReceptor ErbB-2TrastuzumabValor predictivo de las pruebasVolumen sistólico10.1016/j.breast.2020.09.0011532-3080PMC7511727http://www.thebreastonline.com/article/S0960977620301715/pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511727/pdf